Carlotta Giani
University of Pisa
EndocrinologyPathologyOncologyAdverse effectLenvatinibThyroidectomySorafenibThyroglobulinCalcitoninThyroid cancerMedullary thyroid cancerVandetanibLymph nodeCabozantinibTargeted therapyPapillary thyroid cancerThyroid carcinomaThyroidMedicineGastroenterology
31Publications
9H-index
331Citations
Publications 25
Newest
Introduction [18F]-FDG-PET/CT positive metastatic lesions in radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) have a poor prognosis and lenvatinib represents the best therapy. We investigated the role of [ 18F]-FDG-PET/CT in the evaluation of metabolic response and prediction of the outcome of RAI-R DTC patients treated with lenvatinib. Materials and methods Thirty-three progressive metastatic RAI-R DTC patients treated with lenvatinib were investigated at baseline and during fol...
Source
Differentiated thyroid cancers (DTC) are commonly and successfully treated with total thyroidectomy plus/minus radioiodine therapy (RAI). Medullary thyroid cancer (MTC) is only treated with surgery but only intrathyroidal tumors are cured. The worst prognosis is for anaplastic (ATC) and poorly differentiated thyroid cancer (PDTC). Whenever a local or metastatic advanced disease is present, other treatments are required, varying from local to systemic therapies. In the last decade, the efficacy o...
Source
#1Alessandro Prete (UniPi: University of Pisa)H-Index: 3
#2Marco Falcone (UniPi: University of Pisa)H-Index: 33
Last. Rossella Elisei (UniPi: University of Pisa)H-Index: 68
view all 13 authors...
PURPOSE Severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) is challenging health systems all over the world. Cancer patients have a higher risk of being infected by SARS-Cov-2 and higher coronavirus disease 2019 (COVID-19) severity and mortality. Up to date, there were no data about COVID-19 in patients with thyroid cancer (TCs). The aim of the study was to describe the prevalence of COVID-19 in a well-characterized series of TC patients evaluated for the persistence of the neoplastic ...
Source
PURPOSE Patients with advanced progressive metastatic medullary thyroid cancer (MTC), show poor prognosis and few available systemic therapeutic options. After the loss of clinical benefit with other tyrosine kinase inhibitors (TKI), we evaluated the use of lenvatinib as salvage therapy. METHODS Ten patients who experienced the loss of clinical benefit after treatment with at least one previous TKI, were treated with lenvatinib. We assessed patient's response immediately before, at the first (fi...
Source
#1Carlotta Giani (UniPi: University of Pisa)H-Index: 9
#2Laura ValerioH-Index: 9
Last. Rossella Elisei (UniPi: University of Pisa)H-Index: 68
view all 17 authors...
5 CitationsSource
#1Laura Agate (UniPi: University of Pisa)H-Index: 29
#2Luciana Puleo (UniPi: University of Pisa)H-Index: 4
Last. Rossella Elisei (UniPi: University of Pisa)H-Index: 68
view all 6 authors...
This letter is to confirm and support the data of Nervo et al, recently published on Thyroid journal, and showing a relevant prevalence of biliary disorders in patients affected by advanced thyroid cancer (TC) and treated with lenvima. We also observed a similar prevalence of gallbladder and/or biliary disease in a bigger series of TC treated with lenvima: by combining the Nervo et al. and our data the prevalence of this adverse event is of 16/118 (13.5%) and it seems independent from the starti...
Source
OBJECTIVE At the present, recombinant TSH cannot be used for the treatment of metastatic differentiated thyroid cancer patients. Aim of this study was to evaluate if the type of TSH stimulation, recombinant or endogenous, had an impact on the outcome of these patients. DESIGN AND METHODS We compared the outcome of two propensity score-matched groups of metastatic patients, stimulated by either only recombinant TSH (n=43) or only endogenous TSH (n=34). RESULTS As expected from the matching proced...
Source
#1Carlotta GianiH-Index: 9
#2Teresa RamoneH-Index: 3
Last. Rossella EliseiH-Index: 68
view all 17 authors...
Background. Multiple endocrine neoplasia type 2 (MEN2) is a hereditary cancer syndrome caused by RET proto-oncogene mutation. Two different clinical variants of MEN2 are known (MEN2A and MEN2B): medullary thyroid carcinoma (MTC) almost always present and associated with pheochromocytoma (Pheo), and primary hyperparathyroidism (HPTH) in MEN2A and with Pheo and other nonendocrine diseases in MEN2B. Case Report. A 7-year-old girl, previously treated for a pelvic plexiform neurofibroma, arrived at o...
Source
#1Antonio MatroneH-Index: 10
#2Virginia CappagliH-Index: 9
Last. Rossella EliseiH-Index: 68
view all 12 authors...
Source
#1Laura Valerio (UniPi: University of Pisa)H-Index: 9
#2Antonio Matrone (UniPi: University of Pisa)H-Index: 10
Last. Rossella Elisei (UniPi: University of Pisa)H-Index: 68
view all 9 authors...
Source